[Cost-effectiveness aspects of benign prostatic hyperplasia (BPH) therapy].
The paper is concerned with general cost-effective approaches to management of BPH: problems of treatment and patients choice, cost of different treatments, examinations, time of the response onset, effective doses, regimens, side effects. Mathematical estimations show that of three groups of drugs (alpha 1-adrenoblockers, phytopreparations, finasteride), alpha 1-adrenoblockers are most effective as to minimal time to the start of clinical effect, while once-a-day regimen was the cheapest of the dose regimens. Of alpha 1-adrenoblockers, hemodynamically low-active preparations (tamsulosin) are preferable.
Lopatkin
N A
NA
Ziborova
I V
IV
Sivkov
A V
AV
Apolikhin
O I
OI
D058891:5-alpha Reductase Inhibitors; D000317:Adrenergic alpha-Antagonists / Q000191:economics* / Q000627:therapeutic use; D000972:Antineoplastic Agents, Phytogenic / Q000191:economics* / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D004791:Enzyme Inhibitors / Q000191:economics* / Q000627:therapeutic use; D018120:Finasteride / Q000191:economics / Q000627:therapeutic use; D006801:Humans; D008297:Male; D011470:Prostatic Hyperplasia / Q000188:drug therapy / Q000191:economics*
D058891:5-alpha Reductase Inhibitors; D000317:Adrenergic alpha-Antagonists; D000972:Antineoplastic Agents, Phytogenic; D004791:Enzyme Inhibitors; D018120:Finasteride